{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:52Z","timestamp":1791825352859,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jns.2026.125740","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:13:20Z","timestamp":1767658400000},"page":"125740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: A retrospective cohort study of two national databases"],"prefix":"10.1016","volume":"481","author":[{"given":"Nilay","family":"McLaren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia Zurinaga","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jns.2026.125740_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.jns.2026.125740_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41582-020-0345-3","article-title":"New insights into very-late-onset myasthenia gravis","volume":"16","author":"Barnett","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125740_bb0015","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.1038\/s41467-024-53595-6","article-title":"Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction","volume":"15","author":"Braun","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jns.2026.125740_bb0020","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cortes-Vicente","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2026.125740_bb0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.26169","article-title":"Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease","volume":"90","author":"Handunnetthi","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2026.125740_bb0030","article-title":"A distinct immunological signature in late-onset myasthenia gravis: insights from an exploratory proteomics study","author":"Roy","year":"2025","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.125740_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.jns.2026.125740_bb0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.125740_bb0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.jns.2026.125740_bb0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jns.2026.125740_bb0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"issue":"20","key":"10.1016\/j.jns.2026.125740_bb0060","first-page":"2006","article-title":"Randomized trial of thymectomy in Myasthenia Gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11\u221212","key":"10.1016\/j.jns.2026.125740_bb0065","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.jns.2026.125740_bb0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.21191","article-title":"Racial differences in myasthenia gravis in Alabama","volume":"39","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jns.2026.125740_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200503","article-title":"Understanding racial and ethnic disparities in myasthenia gravis outcomes: EXPLORE-MG registry experience","volume":"15","author":"McLaren","year":"2025","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jns.2026.125740_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116830","article-title":"Exploring outcomes and characteristics of myasthenia gravis: rationale, aims and design of registry - the EXPLORE-MG registry","volume":"414","author":"Anil","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.125740_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1448803","article-title":"Racial disparities in acute care utilization among individuals with myasthenia gravis","volume":"13","author":"Qi","year":"2025","journal-title":"Front. Public Health"},{"issue":"4","key":"10.1016\/j.jns.2026.125740_bb0090","first-page":"791","article-title":"Possible sex and racial disparities in myasthenia gravis care","volume":"70","author":"Suresh","year":"2024","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jns.2026.125740_bb0095","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000524733","article-title":"Are there racial differences in inpatient outcomes and treatment utilization following hospitalization for myasthenia gravis exacerbation?","volume":"56","author":"Syed","year":"2022","journal-title":"Neuroepidemiology"},{"issue":"14","key":"10.1016\/j.jns.2026.125740_bb0100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMp2215609","article-title":"Why diverse clinical trial participation matters","volume":"388","author":"Schwartz","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.125740_bb0105","author":"NIS OVERVIEW"},{"issue":"7","key":"10.1016\/j.jns.2026.125740_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4240","article-title":"Racial disparities in patient characteristics and survival after acute myocardial infarction","volume":"1","author":"Graham","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.jns.2026.125740_bb0115","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1001\/jamainternmed.2014.5430","article-title":"Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease","volume":"174","author":"Lindenauer","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125740_bb0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","article-title":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","volume":"122","author":"Laconi","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.jns.2026.125740_bb0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40120-025-00711-3","article-title":"Risk of exacerbation and level of healthcare resource utilization in myasthenia gravis assessed by myasthenia gravis activities of daily living score","volume":"14","author":"Ting","year":"2025","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.jns.2026.125740_bb0130","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/mus.25624","article-title":"Inpatient cost analysis for treatment of myasthenia gravis","volume":"56","author":"Omorodion","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2026.125740_bb0135","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0108","article-title":"Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data","volume":"13","author":"Pisc","year":"2024","journal-title":"J. Comp. Eff. Res."},{"issue":"2","key":"10.1016\/j.jns.2026.125740_bb0140","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207863","article-title":"Hospitalizations and mortality from myasthenia gravis: trends from 2 US National Datasets","volume":"102","author":"Habib","year":"2024","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2026.125740_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110564","article-title":"Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls","volume":"27","author":"Bhandage","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.jns.2026.125740_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5114\/aoms\/89768","article-title":"Relationship between age and in-hospital mortality during 15,345,025 non-surgical hospitalizations","volume":"17","author":"Walicka","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"2","key":"10.1016\/j.jns.2026.125740_bb0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jns.2026.125740_bb0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000539577","article-title":"Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review","volume":"59","author":"Sciancalepore","year":"2025","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2026.125740_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1339167","article-title":"Epidemiology of myasthenia gravis in the United States","volume":"15","author":"Ye","year":"2024","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125740_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000241","article-title":"New and emerging treatments for myasthenia gravis","volume":"2","author":"DeHart-McCoyle","year":"2023","journal-title":"BMJ Med."},{"key":"10.1016\/j.jns.2026.125740_bb0175","series-title":"Quick Facts United States","author":"Bureau USC","year":"2023"},{"key":"10.1016\/j.jns.2026.125740_bb0180","author":"Bureau USC"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:22:05Z","timestamp":1774275725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S0022510X26000213"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125740","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: A retrospective cohort study of two national databases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125740"}}